LDL-C Impact Calculator

How many lives could you save in your own practice through effective and sustained LDL-C reduction?

A broad evidence base over the last 50 years has demonstrated that consistent and sustained reductions of LDL-C are associated with reductions in major adverse CV events (MACE) and CV death.^1-3 This is further reinforced by international clinical treatment guidelines.^4-5

The LDL-C impact calculator has been developed to support healthcare professionals (HCPs) connect this data with the potential impact of reducing LDL-C over a sustained period of time in your own patients/populations, demonstrating how many lives could be saved, along with how many CV events could be avoided, with effective and sustained LDL-C reduction in your own healthcare setting.

The calculator is a computer-based simulation, which requires the following input values:
	The number of patients with atherosclerotic cardiovascular disease (ASCVD) and/or the number of primary prevention patients with HeFH, managed in a specific healthcare setting (e.g. your own practice) and their average LDL-C
	How many of those patients are believed to be below LDL-C guideline targets       Research has shown that up to 80% of ASCVD patients have LDL-C levels >70 mg/dL6
	An estimated LDL-C reduction for those patients
Please note that for the default LDL-C reduction values for ASCVD and HeFH, inclisiran has been used as an example, with values of 52%7 and 48%8 respectively. This estimate is based on Inclisiran LDL-C reduction in ORION-10 and ORION-9 in the target population. Note that these default values have been used as an example and may be modified in the input tab. Please also note that inclisiran does not have cardiovascular (CV) outcomes data and the effect of inclisiran on CV morbidity and mortality has not been determined. The data and the figures are intended to act as a guide only and do not necessarily represent actual practice. The outputs generated by the tool should be considered as computer-generated forecast guidance only.

The LDL-C impact calculator provides you with a computer generated forecast of:
	The potential lives saved with effective and sustained LDL-C reduction over 10 years (or the relevant time frame) in your own practice
	The MACE avoided and decrease in MI/strokes by effective and sustained LDL-C reduction over 10 years (or the relevant time frame) in your own practice
Please note that the data and the figures are intended to act as a guide only and do not necessarily represent actual practice. The outputs generated by the tool should be considered as computer-generated forecast guidance only. Please refer to the methodology tab for further information on the computer-generated forecast.

Please use below credentials to login:

Username: [email protected]          Password: hcpbasecase@2021

References:

1. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-1405. Lancet. 2015;385(9976):1397-1405. 

2. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. 

3. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–1297. doi:10.1001/jama.2016.13985. 

4. Mach F, Baigent C, Catapano Al, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;411(1):111-188 

5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol.2019;139(25):e1082-e1143. 

6. Cannon C, Khan I, Klimchak A, Reynolds M, Sanchez R, Sasiela W. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017;2(9):959-966. doi:10.1001/jamacardio.2017.2289 

7. Ray KK, Wright RS, Kallend D, et al.; ORION-9 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. 

8. Raal FJ, Kallend D, Ray KK, et al; ORION-10 and ORION-11 Investigators. lnclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530.